DAFNA Capital Management’s Cymabay Therapeutics CBAY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-171,059
| Closed | -$1.07M | – | 80 |
|
|
2022
Q4 | $1.07M | Sell |
171,059
-1,532,176
| -90% | -$9.61M | 0.3% | 51 |
|
|
2022
Q3 | $5.96M | Sell |
1,703,235
-84,334
| -5% | -$295K | 1.6% | 20 |
|
|
2022
Q2 | $5.27M | Buy |
1,787,569
+95,000
| +6% | +$280K | 1.44% | 23 |
|
|
2022
Q1 | $5.26M | Sell |
1,692,569
-95,000
| -5% | -$295K | 1.37% | 21 |
|
|
2021
Q4 | $6.04M | Buy |
1,787,569
+1,263,283
| +241% | +$4.27M | 1.52% | 19 |
|
|
2021
Q3 | $1.91M | Buy |
524,286
+13,900
| +3% | +$50.7K | 0.51% | 47 |
|
|
2021
Q2 | $2.23M | Buy |
510,386
+172,616
| +51% | +$753K | 0.47% | 47 |
|
|
2021
Q1 | $1.53M | Buy |
+337,770
| New | +$1.53M | 0.36% | 63 |
|
|
2020
Q3 | – | Sell |
-165,600
| Closed | -$578K | – | 92 |
|
|
2020
Q2 | $578K | Buy |
+165,600
| New | +$578K | 0.17% | 73 |
|
|
2019
Q4 | – | Sell |
-349,996
| Closed | -$1.79M | – | 90 |
|
|
2019
Q3 | $1.79M | Hold |
349,996
| – | – | 0.67% | 37 |
|
|
2019
Q2 | $2.51M | Buy |
349,996
+71,185
| +26% | +$510K | 0.94% | 30 |
|
|
2019
Q1 | $3.7M | Sell |
278,811
-53,700
| -16% | -$713K | 1.6% | 21 |
|
|
2018
Q4 | $2.62M | Buy |
332,511
+38,000
| +13% | +$299K | 1.3% | 26 |
|
|
2018
Q3 | $3.26M | Hold |
294,511
| – | – | 1.34% | 23 |
|
|
2018
Q2 | $3.95M | Sell |
294,511
-29,332
| -9% | -$394K | 1.85% | 18 |
|
|
2018
Q1 | $4.21M | Sell |
323,843
-37,321
| -10% | -$485K | 2.05% | 17 |
|
|
2017
Q4 | $3.32M | Sell |
361,164
-73,836
| -17% | -$679K | 1.79% | 20 |
|
|
2017
Q3 | $3.51M | Buy |
435,000
+415,933
| +2,181% | +$3.35M | 2.18% | 11 |
|
|
2017
Q2 | $110K | Sell |
19,067
-69,000
| -78% | -$398K | 0.08% | 73 |
|
|
2017
Q1 | $379K | Buy |
+88,067
| New | +$379K | 0.32% | 58 |
|